Bioventus (BVS) Stock Overview
A medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BVS from our risk checks.
BVS Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Bioventus Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.49 |
| 52 Week High | US$14.38 |
| 52 Week Low | US$6.02 |
| Beta | 0.84 |
| 1 Month Change | 2.20% |
| 3 Month Change | -17.01% |
| 1 Year Change | -8.20% |
| 3 Year Change | -17.64% |
| 5 Year Change | n/a |
| Change since IPO | -66.22% |
Recent News & Updates
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
May 07
Recent updates
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
May 07Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues
Mar 08Bioventus: Amply Rewarded For Recent Progress
Jan 05Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Aug 12Bioventus: Bullish On Path To Profitability
Jan 24Bioventus: Reiterating Buy Thesis Following Q2 Earnings
Sep 08Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M
Aug 11Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal
Aug 03Bioventus: Strong Value Gap, Insulated Via Leading Market Share
Jun 14Shareholder Returns
| BVS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -12.2% | -3.2% | 0.5% |
| 1Y | -8.2% | 7.6% | 14.1% |
Return vs Industry: BVS underperformed the US Medical Equipment industry which returned 7.3% over the past year.
Return vs Market: BVS underperformed the US Market which returned 12.4% over the past year.
Price Volatility
| BVS volatility | |
|---|---|
| BVS Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BVS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BVS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 930 | Rob Claypoole | www.bioventus.com |
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
Bioventus Inc. Fundamentals Summary
| BVS fundamental statistics | |
|---|---|
| Market cap | US$440.61m |
| Earnings (TTM) | -US$31.29m |
| Revenue (TTM) | US$567.70m |
Is BVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVS income statement (TTM) | |
|---|---|
| Revenue | US$567.70m |
| Cost of Revenue | US$184.80m |
| Gross Profit | US$382.90m |
| Other Expenses | US$414.19m |
| Earnings | -US$31.29m |
Last Reported Earnings
Mar 29, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 67.45% |
| Net Profit Margin | -5.51% |
| Debt/Equity Ratio | 186.5% |
How did BVS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/17 17:49 |
| End of Day Share Price | 2025/07/17 00:00 |
| Earnings | 2025/03/29 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bioventus Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |
| Kyle Rose | Canaccord Genuity |